MediPharm Labs Past Earnings Performance
Past criteria checks 0/6
MediPharm Labs's earnings have been declining at an average annual rate of -22.4%, while the Pharmaceuticals industry saw earnings growing at 26.2% annually. Revenues have been declining at an average rate of 19.9% per year.
Key information
-22.4%
Earnings growth rate
-6.7%
EPS growth rate
Pharmaceuticals Industry Growth | 23.1% |
Revenue growth rate | -19.9% |
Return on equity | -28.5% |
Net Margin | -53.2% |
Next Earnings Update | 27 Mar 2024 |
Recent past performance updates
Recent updates
Market Might Still Lack Some Conviction On MediPharm Labs Corp. (TSE:LABS) Even After 31% Share Price Boost
Mar 23Does MediPharm Labs (TSE:LABS) Have A Healthy Balance Sheet?
Jan 10MediPharm Labs (TSE:LABS) Has Debt But No Earnings; Should You Worry?
Sep 06MediPharm Labs Corp. (TSE:LABS) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable
Apr 17Time To Worry? Analysts Just Downgraded Their MediPharm Labs Corp. (TSE:LABS) Outlook
Aug 20Some Analysts Just Cut Their MediPharm Labs Corp. (TSE:LABS) Estimates
May 21Things Look Grim For MediPharm Labs Corp. (TSE:LABS) After Today's Downgrade
Apr 06Is MediPharm Labs (TSE:LABS) Using Too Much Debt?
Mar 07Does MediPharm Labs (TSE:LABS) Have A Healthy Balance Sheet?
Aug 18Some MediPharm Labs Corp. (TSE:LABS) Analysts Just Made A Major Cut To Next Year's Estimates
May 23Reflecting on MediPharm Labs' (TSE:LABS) Share Price Returns Over The Last Year
Jan 11Revenue & Expenses BreakdownBeta
How MediPharm Labs makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 23 | 30 | -16 | 23 | 0 |
30 Jun 23 | 28 | -19 | 22 | 1 |
31 Mar 23 | 23 | -26 | 21 | 1 |
31 Dec 22 | 22 | -30 | 24 | 1 |
30 Sep 22 | 22 | -46 | 32 | 2 |
30 Jun 22 | 20 | -46 | 32 | 2 |
31 Mar 22 | 21 | -48 | 32 | 1 |
31 Dec 21 | 22 | -55 | 31 | 2 |
30 Sep 21 | 22 | -64 | 22 | 2 |
30 Jun 21 | 22 | -72 | 23 | 1 |
31 Mar 21 | 30 | -63 | 25 | 2 |
31 Dec 20 | 36 | -66 | 28 | 2 |
30 Sep 20 | 62 | -39 | 35 | 2 |
30 Jun 20 | 101 | -20 | 35 | 2 |
31 Mar 20 | 118 | -15 | 33 | 2 |
31 Dec 19 | 129 | 2 | 31 | 1 |
30 Sep 19 | 107 | 1 | 22 | 0 |
30 Jun 19 | 64 | -4 | 17 | 0 |
31 Mar 19 | 32 | -8 | 12 | 0 |
31 Dec 18 | 10 | -8 | 6 | 0 |
30 Sep 18 | 0 | -6 | 4 | 0 |
30 Jun 18 | 0 | -4 | 3 | 0 |
31 Mar 18 | 0 | -2 | 2 | 0 |
31 Dec 17 | 0 | -1 | 1 | 0 |
Quality Earnings: LABS is currently unprofitable.
Growing Profit Margin: LABS is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: LABS is unprofitable, and losses have increased over the past 5 years at a rate of 22.4% per year.
Accelerating Growth: Unable to compare LABS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LABS is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (100.1%).
Return on Equity
High ROE: LABS has a negative Return on Equity (-28.49%), as it is currently unprofitable.